Table 1.
Number of Patients/ Date/Country | Age/Sex | Infectious Focus | Species | Anti-GM-CSF Antibodies | Treatment | Evolution | Ref |
---|---|---|---|---|---|---|---|
32 patients | 65% male | 75% pulmonar (n = 24) | Nocardia asteroides 19 (59%) | Not performed | Unspecified antibiotherapy (n = 20) Surgery (n = 6) |
41% died | 5 |
1950–2010 | 35% female | 19% (n = 6) cerebral | Nocardia brasiliensis 1 (3%) | ||||
Worldwide | Mean age 35 | 6% other (n = 2) | Nocardia farcinica 1 (3%) | ||||
Nocardia spp 11 (34%) | |||||||
1 patient | 37/male | Pulmonar | NA | Presence | NA | NA | 6 |
2010 | |||||||
Japan | |||||||
2 patients | NA | NA | NA | NA | NA | NA | 7 |
1990–2010 China |
|||||||
1 patient | 50/male | Pulmonar | N farcinica | Not performed | Amikacin 6 weeks and TMP-SMX 6 months | Full recovery | 8 |
2014 | |||||||
Spain | |||||||
1 patient | 42/male | Cerebral abscesses | N asteroids | Not performed | TMP-SMX, meropenem and amikacin 2 months, relayed TMP-SMX | No improvement | 9 |
2015 | |||||||
Iran | |||||||
1 patient | 49/male | Cerebral abscess | N farcinica | Not performed | 12 months of AMC and minocycline | Full recovery | 10 |
2017 | |||||||
Spain | |||||||
1 patient | NA | NA | NA | Not performed | Adapted antibiotherapy (not specified) | Full recovery | 11 |
2002–2016 | |||||||
Brazil | |||||||
1 patient | 62/male | Pulmonar | N brasiliensis | Presence | Amikacin 6 weeks and TMP-SMX 6 months | Full recovery | 12 |
2020 | |||||||
United States | |||||||
1 patient | 40/male | Cerebral abscess | Nocardia abscessus | Presence | Meropenem 6 weeks and TMP-SMX 12 months | Full recovery | Our case |
2018 | |||||||
France |
Abbreviations: AMC, amoxicillin/clavulanate; GM-CSF, granulocyte macrophage colony-stimulating factor; NA, not available; Ref, reference; TMP-SMX, trimethoprim-sulfamethoxazole.